Premium
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck
Author(s) -
Tam Samantha,
Gajera Mona,
Luo Xiaoning,
Glisson Bonnie S.,
Ferrarotto Renata,
Johnson Faye M.,
Mott Frank E.,
Gillison Maura L.,
Lu Charles,
Le Xiuning,
Blumenschein George R.,
Wong Michael K.,
Rosenthal David I.,
Nagarajan Priyadharsini,
ElNaggar Adel K.,
Midgen Michael R.,
Weber Randal S.,
Myers Jeffrey N.,
Gross Neil D.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26626
Subject(s) - medicine , systemic therapy , radiation therapy , oncology , targeted therapy , head and neck squamous cell carcinoma , immunotherapy , cytotoxic t cell , head and neck , head and neck cancer , surgery , cancer , biochemistry , chemistry , breast cancer , in vitro
Background The outcomes of patients treated with cytotoxic or targeted systemic therapy is not well defined for cutaneous squamous cell carcinoma of the head and neck (cSCCHN). Methods Patients with cSCCHN treated with cytotoxic or targeted systemic therapy were included. Patients were divided into two groups based on the presence of distant metastasis (M1 vs. M0) at presentation. A proportional hazards model was used to assess for independent predictors of overall survival. Results Of 129 patients with cSCCHN, 20 (16%) were M1 and 109 (84%) were M0. Independent predictors of improved survival were M0 status, treatment of locally advanced disease with radiotherapy, and lower Eastern Cooperative Oncology Group (ECOG) score. Conclusions Survival was worse in M1 patients treated with cytotoxic or targeted systemic therapy and poor baseline performance status but improved in those receiving radiotherapy. These data can serve as historical controls for future systemic therapy trials, including immunotherapy.